

**Table 2.9. Cohort studies of estrogen-only menopausal therapy and urinary bladder cancer**

Reference, location, name of study	Cohort description	Exposure assessment	Organ site (ICD code)	Exposure categories	No. of cases	Relative risk (95% CI)	Adjustment for potential confounders	Comments	
Cantwell <i>et al.</i> (2006) USA	54,308 postmenopausal women (mean age at start of follow-up, 58 years) identified from 29 screening centers throughout the United States, participants in the Breast Cancer Detection Demonstration Project (BCDDP); 2082 breast cancer cases identified during follow-up for an average of 15.43 years.	Mailed questionnaire or telephone interview	Urinary bladder cancer	Never used hormone therapy	53	1.0	Age, calendar year, smoking status	The primary type of estrogen used was conjugated estrogens (Premarin).	
				Estrogen only					1.15 (0.81-1.63)
				<i>Ever use</i>	51				
				<i>Duration of use (years)</i>					
				<4	25	1.55 (0.96-2.51)			
				4-9	9	1.00 (0.49-2.04)			
10-19	10	1.23 (0.62-2.43)							
≥ 20	2	0.57 (0.14-2.34)							
McGrath <i>et al.</i> , (2006) USA 1976–2002	84,330 women aged 30–55 years in 1980, followed to 2002, in the Nurses’ Health Study; 22,540 were post-menopausal	Mailed questionnaire	Urinary bladder cancer	Never used hormone therapy	85	1.00	Age, time period, smoking status, pack-years of smoking, body mass index		
				Current use estrogen only	39	1.05 (0.71-1.54)			
Prizment <i>et al.</i> (2007) USA 1986–2003	The Iowa Women’s Health Study, a cohort of 37,459 postmenopausal women followed from 1986 through 2003. Cases identified by linkage to the Iowa State health Registry.	Mailed questionnaire	Urinary bladder cancer	Estrogen use		HR	Age, smoking status and pack-years		
				Never	114	1.00			
				Current/past	78	1.04 (0.78-1.39)			